大華繼顯:維持雅各臣科研製藥(2633.HK)“買入”評級 目標價降至1.82港元
大華繼顯發表研究報告,預期雅各臣科研製藥(2633.HK)在社會不穩的情況下,盈利仍可穩定增長,並認為其股價疲軟提供入市機會,維持“買入”的投資評級,但將目標價由2.16港元下調15.7%至1.82港元,以反映市場情緒疲弱。
報告指,儘管香港社會不穩,但公司本地營運不受影響。該行表示,公司持續擴張業務及提升營運效益;加上,公司發行可換股債券,料將有助降低財務成本。該行相信,公司業務具防守性,料其2020財年收入及盈利可分別按年增長9%及20%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.